Trial · NCT03567291
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined | TEV-50717 | At least one adverse event | 161 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined | TEV-50717 | At least one serious adverse event | 2 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined | TEV-50717 | At least one severe adverse event | 6 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined | TEV-50717 | At least one AE related to investigational product | 95 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined | TEV-50717 | At least one adverse event leading to withdrawal | 14 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized TEV-50717 | At least one adverse event | 16 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized Placebo | At least one adverse event | 6 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized TEV-50717 | At least one serious adverse event | 0 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized Placebo | At least one serious adverse event | 0 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized TEV-50717 | At least one severe adverse event | 0 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized Placebo | At least one severe adverse event | 0 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized TEV-50717 | At least one AE related to investigational product | 6 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized Placebo | At least one AE related to investigational product | 1 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized TEV-50717 | At least one adverse event leading to withdrawal | 0 | Participants | |
| Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) | Randomized Placebo | At least one adverse event leading to withdrawal | 0 | Participants | |
| Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score | TEV-50717 | CDI-2 Parent Version Week 2 | -0.7 | Standard Deviation 4.26 | Units On A Scale |
| Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score | TEV-50717 | CDI-2 Parent Version Week 4 | -1.5 | Standard Deviation 4.39 | Units On A Scale |
| Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score | TEV-50717 | CDI-2 Parent Version Week 8 | -1.5 | Standard Deviation 5.0 | Units On A Scale |
| Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score | TEV-50717 | CDI-2 Parent Version Week 15 | -1.2 | Standard Deviation 5.79 | Units On A Scale |
| Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score | TEV-50717 | CDI-2 Parent Version Week 28 | -1.1 | Standard Deviation 5.52 | Units On A Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03567291/results